Since there was a discrepancy between B6CaP and MB49 in terms of percentage TAM levels after JHU083 treatment, we investigated whether JHU083-induced changes were related to the intratumoral abundance of M1 (live CD45+Ly6C−Ly6G−F4/80+MHCII+CD86+) or M2 (live CD45+Ly6C−Ly6G−F4/80+CD206+) TAMs in both tumor types. The gene discussed is CD86; the disease is neoplasm.